Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 26;62(5):e02380-17.
doi: 10.1128/AAC.02380-17. Print 2018 May.

In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens

Susanne Paukner  1 , Astrid Gruss  2 , Jørgen Skov Jensen  3
Affiliations

In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens

Susanne Paukner et al. Antimicrob Agents Chemother. .

Abstract

The pleuromutilin antibiotic lefamulin demonstrated in vitro activity against the most relevant bacterial pathogens causing sexually transmitted infections (STI), including Chlamydia trachomatis (MIC50/90, 0.02/0.04 mg/liter; n = 15), susceptible and multidrug-resistant Mycoplasma genitalium (MIC range, 0.002 to 0.063 mg/liter; n = 6), and susceptible and resistant Neisseria gonorrhoeae (MIC50/90, 0.12/0.5 mg/liter; n = 25). The results suggest that lefamulin could be a promising first-line antibiotic for the treatment of STI, particularly in populations with high rates of resistance to standard-of-care antibiotics.

Keywords: Chlamydia trachomatis; Mycoplasma genitalium; Neisseria gonorrhoeae; lefamulin; pleuromutilin; sexually transmitted diseases; sexually transmitted infection.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, Stevens G, Gottlieb S, Kiarie J, Temmerman M. 2015. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One 10:e0143304. doi:10.1371/journal.pone.0143304. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention. 2015. Sexually transmitted disease surveillance 2014. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
    1. Taylor-Robinson D, Jensen JS. 2011. Mycoplasma genitalium: from chrysalis to multicolored butterfly. Clin Microbiol Rev 24:498–514. doi:10.1128/CMR.00006-11. - DOI - PMC - PubMed
    1. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M. 2011. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 55:3538–3545. doi:10.1128/AAC.00325-11. - DOI - PMC - PubMed
    1. Unemo M, Shafer WM. 2014. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 27:587–613. doi:10.1128/CMR.00010-14. - DOI - PMC - PubMed

Publication types

MeSH terms